Cytosorbents (CTSO)

The company’s best-known product platform is CytoSorb, an extracorporeal blood purification cartridge used with compatible blood pumps and dialysis or heart-lung machine circuits. In markets where it is approved, CytoSorb is used in intensive care and operating room settings, including for patients with septic shock, severe inflammatory response, liver failure and other life-threatening conditions. Cytosorbents has also developed applications aimed at reducing the risk of serious bleeding by removing antithrombotic drugs during urgent or high-risk cardiothoracic surgery.

Cytosorbents operates in a specialised segment of the healthcare market that sits between critical care medicine, cardiovascular surgery and extracorporeal therapies. Its commercial footprint is most developed in Europe, particularly Germany, while the company continues to pursue regulatory and clinical pathways in the United States and other regions. Adoption depends on clinical evidence, physician experience, reimbursement, hospital purchasing decisions and regulatory approvals.

For investors, CTSO represents a small-cap medtech company built around a proprietary blood purification platform. Its opportunity is tied to expanding approved indications, generating supportive clinical data and increasing use in hospitals that treat patients with complex inflammatory or bleeding risks.